PFIZER CONFIRMS U.S. PATENT TERM EXTENSION FOR IBRANCE UNTIL MARCH 2027
The Pharma Data
FEBRUARY 8, 2021
RE47,739 (‘739) by more than four years until March 5, 2027. Across clinical trials (PALOMA-1, PALOMA-2, PALOMA-3), 1.0% Patent Term Extension (PTE) certificate for IBRANCE® (palbociclib). The certificate extends the term of U.S. of IBRANCE-treated patients had ILD/pneumonitis of any grade, 0.1%
Let's personalize your content